PI: Nathan Shock Center of Excellence in the Biology of Aging
PI: Glenn Center for the Biology of Human Aging.
Co-Scientific Director of the American Federation for Aging Research
Founder and on the Board of CohBar Inc.
Chief Medical Advisor for Life Bioscience
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn center. He was the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies.
He is the author of over 270 peer-reviewed papers and a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions.
Dr. Barzilai is on the board of AFAR, its scientific director and a founding member of the Academy for Lifespan and Health span. He co-founded CohBar and Lifebioscinces. He has been featured in major papers, TV program and documentaries (2 TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, Prime Minister office in Israel, several International Banks, The Vatican, Pepsico, Milken Institute, Davos Economical Forum, and featured in The Wall Street Journal, New York Times, The Economist and Wired Magazine. His book Age Later was published in the June of 2020.
Dr. Nathan Price is Chief Scientific Officer of Thorne HealthTech (NASDAQ: THRN). Previously he was CEO of Onegevity, an AI health intelligence company that merged with Thorne prior to the IPO in 2021. In 2019, he was named as one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine, and in 2021 he was appointed to the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine. He spent much of his earlier career as Professor and Associate Director of the Institute for Systems Biology (now on leave), co-director with biotechnology pioneer Lee Hood of the Hood-Price Lab for Systems Biomedicine, and is Affiliate Faculty at the University of Washington in Bioengineering and Computer Science & Engineering. He is a Camille Dreyfus Teacher-Scholar, received the 2016 Grace A. Goldsmith award for his work pioneering 'scientific wellness', was a co-founder of Arivale, and received a Healthy Longevity Catalyst Award from the National Academy of Medicine in 2020. He has co-authored more than 180 peer-reviewed scientific publications and given over 200 talks and keynotes. He also served as Chair of the NIH Study Section on Modeling and Analysis of Biological Systems (MABS).
Kevin Perrott is a successful businessman and owner of a large snowmobile and motorcycle dealership in Canada. After becoming a cancer survivor he decided to focus his efforts on the study of age-related disease and obtained a Ph.D. for work studying natural compounds effects on the inflammation produced by senescent cells in the lab of Judith Campisi at the Buck Institute for Research on Aging. He is Treasurer and co-founder of SENS Research Foundation and former Director of the Methuselah Foundation. He also cofounded Oisin Biotechnologies, a for-profit fighting aging through 'reprogramming' biology. After years of working in both the for-profit and non-profit sectors to accelerate the development of interventions in aging, it became clear that a large reason for the delay is lack of involvement of the consumer and he became the Founder and CEO of OpenCures, a for-benefit enterprise that has created a platform that enables collaboration and synergies between customers and the companies who develop health technologies.
Dr. Ronjon Nag is an inventor and entrepreneur. He is a founder and advisor/board member of multiple start-ups. His companies have been sold to Apple, BlackBerry, and Motorola. He has been awarded the Mountbatten Medal in the Royal Institution by the Institution of Engineering and Technology and has been the winner (Bounce Imaging-Board) of the $1m Verizon Powerful Answers Award. He has been a pioneer of smartphones and the 'app stores' they depend on.
He has worked on neural networks, touch screens, mobile search, voice recognition, text prediction, and handwriting recognition. He has a Ph.D. from Cambridge, an M.S from M.I.T, and a B.Sc. from Birmingham in the UK. Additionally, he is a Stanford Distinguished Careers Institute Interdisciplinary Fellow based at the Stanford Center for Language and Information (CSLI).
Fascinated from a young age by how a single cell forms the whole human body following an innate genetic program, Jean M. Hébert became driven by how knowledge of this process might be used to improve our biological fates and defeat aging. To this end, he first trained as a molecular geneticist, obtaining his Ph.D. from the University of California, San Francisco, before specializing in the study of how neural stem cells form the brain at Stanford University. He is now a Professor of Neuroscience and Genetics at the Albert Einstein College of Medicine in New York, where he is developing ways to use cell and tissue replacements to repair and rejuvenate the brain.
Professor de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his Ph.D. in 2004 from the University of Namur in Belgium. Following a postdoc with genomics pioneer Prof George Church at Harvard Medical School, in 2008 Prof de Magalhaes was recruited to the University of Liverpool. He now leads the Integrative Genomics of Ageing Group which focuses on understanding the genetic, cellular, and molecular mechanisms of aging. Professor de Magalhaes has authored over 100 publications and given over 100 invited talks, including three TEDx talks. He is also Chief Scientific Officer of Swiss-based biotech Centaura. His ultimate goal is to develop interventions that preserve health and fend off age-related diseases by manipulating the aging process.
Previously, as Head of Applied Artificial Intelligence at Macro-Eyes, Inc working hand-in-hand with the Bill and Melinda Gates Foundation, he helped build and mentor a diverse, global team of rock star data scientists. Before that, Ram was a Senior Data Scientist at the Fred Hutchinson Cancer Research Center, building novel AI applications to drive biomedical discoveries from large image and genomic datasets. Prior to it, Ram was part of a pioneering collaboration between Google, Inc and the Institute for Systems Biology in Seattle, building Cloud Platform-enabled data science applications for the International Cancer Genome Anatomy Project.
Ram’s long-standing interest in human longevity research is well reflected in the contributions he made to the longevity gene hunt for the International Turtle Genome Sequencing Project.
Ram’s honors and awards include being the only British Council Researcher Exchange Program award winner in 2007 from India, a Young Scientist Award from the Government of India, and an invited external grants reviewer for the Governments of Poland and Hong Kong.
When not researching or communicating science, Ram can be found spending time with his wife and daughter while binge-watching Chuck Lorre sit-coms on CBS or checking out the newest restaurant in town.
Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies.
He is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch). He has received multiple awards, including NYAS Future Entrepreneur recognized by the New York Academy of Sciences, and is named under the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland.
Research interests: Our recent work has shown that many health- and longevity-promoting interventions re-activate the expression of extracellular matrix (ECM) genes during aging (Ewald et al., Nature 2015, PMID:25517099). This ECM enhancement is required and sufficient for extending the lifespan of C. elegans. Our research efforts are focusing on exploring the mechanism(s) of how prolonged ECM homeostasis promotes healthy aging.
Expertise: C. elegans ECM, aging, protein aggregation, neurodegeneration (Alzheimer's disease), Insulin/IGF-1 signaling, NADPH oxidases, ROS, oxidative stress, automated lifespan assessment, genetic and chemical high-throughput screening.
Lab website: http://ewaldlab.com
Twitter: @CollinEwald
Ravi Bala is an AgeTech Evangelist and a startup mentor in AgeTech and Remote Monitoring. He is a Co-Founder and former Board Member at HealthSignals, LLC, a leader in technology solutions for better senior living. An innovator and an expert in mobile health and digital strategy, he has a successful track record of creating and managing teams of independent thinkers. He has a tenacious dedication to compassion and dignity in the workplace. He is a teacher, a mentor, and a coach at heart and works with many startup ventures as an advisor.
He is currently Chair of the Capital for Good and board member for Girls First Fund – a global effort to end child marriage and is on the Advisory Board of CyberSeniors and the SeniorTrade Blog. He is also a mentor with the Silver Moonshots accelerator and a member of the Drexel University AgeWell Collaboratory. He has taught courses in Digital Strategy in multiple MBA programs in Philadelphia. His latest passion is changing the model of eldercare with the aid of Conversational AI, Robotics and Passive Monitoring.
Completing his Bachelors of Science and Medical degrees from University College Medical School in London his passion for extreme physiology has allowed him to conduct field research across the planet. With expeditions taking him to the sides of Everest, skiing in the Arctic and the European Alps, he has served as a medical officer in the Royal Air Force and at NASA’s Kennedy Space Center. After practicing clinical medicine in London, in 2010, he made the transition to Mumbai where he has worked within the Healthcare and Life-sciences industry as a Strategic advisor, Investor and Operator for a range of MNC and national bellwether firms.
Augmenting his contributions towards global health commentary, the Covid-19 pandemic has brought Marcus back to the frontlines of medicine as a medical volunteer for his city’s fight against controlling the virus. A published author, keynote speaker, digital talk show host and public health commentator, he has been a World Economic Forum’s Global Shaper and is currently a Senior Fellow to the Atlantic Council, working on a project exploring the relationships between the climate crisis and global health. A champion of wellbeing, Marcus is a big believer that sustainably improving the lives of billions of people the world over can only be brought about by enhancing the positive aspects of health rather than focusing solely on pathogenesis and disease.
Marcus is a keen athlete and long distance marathon runner, he holds a Guinness World Record for backwards running and thoroughly enjoys being a father to his two young children.
Raju has over 25 years of experience as a software professional in various roles from developer to architect. Currently, he is working on building bioinformatics software in the cloud that is easy to use and scalable.
Raju is nterested in innovating in the life sciences space to advance human health.
He has acquired a PhD in Physics and Nanotechnology from the Technical University of Denmark and Masters from University of Glasgow. During his PhD, he was handpicked as a Kauffman Global Scholar to embark on a 6 month intensive entrepreneurial training fellowship coordinated by the Kauffman Foundation in collaboration with MIT, Stanford University and Harvard University. He is recipient of numerous research and innovation awards including Outstanding Research-Driven Innovation award from National Research Foundation of Luxembourg.
- Digital Health and EHealth platform development
- Setting up structures for Translational and Entrepreneurial Medicine and business modelling in private-public partnerships
- Implementation of Swiss Health Policy for Highly Specialized Medicine
- Constructing, reorganizing, and merging of hospitals
- Knowledge management and postgraduate training
https://www.linkedin.com/in/slamah/
His transition into Biotech, inspired by medical challenges, was in building and scaling ventures to target pain management with non-opioids and pathogens including SARS-CoV-2 with nanobodies and small molecules. His work was nominated at World Economic Forum COVID-19 Response Challenge in 2020, following his research in Pandemics in 2007. Currently, his venture Lagrangian is scaling Kondor Pharma a Canadian Biotech building nutraceutical and RX products to target inflammation.
He launched Neurometry, where the team is unifying Biomedical Engineering and Neurology to design tools for a Telemedicine Platform with Gamification to diagnose and manage patients with neurological and neurocognitive disorders.
He obtained an M.Sc. (2013) in Quantitative Finance from London Business School, and a BA (Hon) from the University of Toronto in Economics, Statistics, and Theology.
Cumulative experience of 12 years in Healthcare & Life sciences
· Healthcare innovations: Biotech, Digital Health, MedTech, Wellness
· Portfolio management & strategy
· Building partnerships and strategic initiatives
· Business and domain consultancy
Pritam has published more than 40 papers including many in top ranked journals, such as Nature Medicine, Science Advances, Nature Leukemia, Materials Today, Inorganic Chemistry (ACS), Adv. Functional Materials (Wiley) etc. and also serves as referee for various reputed journals. His expertise includes drug designing and discovery, immunoinformatics, molecular modeling, oncology, molecular dynamics, 2D-materials modeling, nano-biotechnology, biophysics, computational materials science and nanomedicine.
Nikolina is a successful serial entrepreneur, CEO, and co-founder of GlycanAge. GlycanAge was founded on a promise that "health care" should start with us caring about our health before we encounter a particular problem.
GlycanAge allows you to measure & influence your longevity by looking at an entirely new part of biology. Glycan biomarkers uniquely encapsulate genetic, epigenetic, and environmental factors driving longevity for every human.Miguel has over 20 years of entrepreneurial and professional experience, building software companies in multiple industries including health care and life sciences. Currently, he’s exploring opportunities in the Longevity Biotech as well as advising other founders and starting in the world of angel investment.
He has experience with management, leadership, software design and architecture, user experience and research, product management, and growth.
Miguel's LinkedIn profile.
PI: Nathan Shock Center of Excellence in the Biology of Aging
PI: Glenn Center for the Biology of Human Aging.
Co-Scientific Director of the American Federation for Aging Research
Founder and on the Board of CohBar Inc.
Chief Medical Advisor for Life Bioscience
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn center. He was the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies.
He is the author of over 270 peer-reviewed papers and a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions.
Dr. Barzilai is on the board of AFAR, its scientific director and a founding member of the Academy for Lifespan and Health span. He co-founded CohBar and Lifebioscinces. He has been featured in major papers, TV program and documentaries (2 TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, Prime Minister office in Israel, several International Banks, The Vatican, Pepsico, Milken Institute, Davos Economical Forum, and featured in The Wall Street Journal, New York Times, The Economist and Wired Magazine. His book Age Later was published in the June of 2020.
Allison Duettmann is the president of Foresight Institute. She leads the Intelligent Cooperation, Molecular Machines, Biotech & Health Extension Groups, shares Foresight's work with the public, e.g. at the Wall Street Journal, SXSW, O'Reilly AI, WEF, The Partnership on AI, Effective Altruism Global, TEDx.She co-edited the book Superintelligence: Coordination & Strategy, and is collaborating on another book on Intelligent Voluntary Cooperation. She holds an MS in Philosophy & Public Policy from the London School of Economics, focusing on AI Safety, and a BA in Philosophy, Politics, Economics from York University.
"WE CANNOT TEACH PEOPLE ANYTHING; WE CAN ONLY HELP THEM DISCOVER IT WITHIN THEMSELVES."
GALILEO GALILEI
